Relieve pain.
Restore function.

SportVis®
for tendon
and ligament injuries^1–3SportVis® for tendon and ligament injuries^1–3SportVis® for tendon
and ligament injuries^1–3

Innovative treatment

The first of its kind

SportVis® is the only Health Canada–authorized hyaluronic acid intended to relieve pain and restore function in damaged tendons and ligaments.¹

It has demonstrated a timely return to normal, pain-free function in patients with chronic lateral epicondylalgia and acute first- and second-degree ankle sprains and is supported by two Canadian clinical trials.

SportVis® with STABHA® targets and treats soft tissue injuries.

Elbow tendon injuryElbow tendon injury

Before treatment

Microscopic tearing in the tendon.

Before treatment
Microscopic tearing in the tendon.
During treatment
SportVis®, containing STABHA®, augments the hyaluronic acid naturally present in the soft tissue surrounding damaged tendons and ligaments. It provides cushioning (support), lubrication, and hydration.
After treatment
SportVis® is clinically proven to provide effective pain relief and restore function.

Ankle ligament injuryAnkle ligament injury

Before treatment

Stretched or torn ligament.

Before treatment
Stretched or torn ligament.
During treatment
SportVis®, containing STABHA®, augments the hyaluronic acid naturally present in the soft tissue surrounding damaged tendons and ligaments. It provides cushioning (support), lubrication, and hydration.
After treatment
SportVis® is clinically proven to provide effective pain relief and restore function.

STABHA®’s soft-tissue-specific biocompatibility is a result of:

▪ A high level of purity
▪ A patented manufacturing process
▪ A generally well-tolerated treatment
- No serious AEs were reported with SportVis®.
- Pain was the most common adverse event.
- For lateral elbow tendinopathy: pain during injection (SportVis® n=3, placebo n=5)
- For ankle sprains: pain (SportVis® n=8, placebo n=7), swelling (SportVis® n=1, placebo n=4), erythema (SportVis® n=2, placebo n=2), and unspecified adverse events (SportVis® n=0, placebo n=2)For ankle sprains: pain (SportVis® n=8, placebo n=7), swelling (SportVis® n=1, placebo n=4), erythema (SportVis® n=2, placebo n=2), and unspecified adverse events (SportVis® n=0, placebo n=2)For ankle sprains: pain (SportVis® n=8, placebo n=7), swelling (SportVis® n=1, placebo n=4), erythema (SportVis® n=2,
placebo n=2), and unspecified adverse events (SportVis® n=0, placebo n=2)

Efficacy and safety

In chronic lateral elbow tendinopathy

Significant improvement in
pain relief lasted 1 year^,†,2Significant improvement in pain relief lasted 1 year^,†,2Significant improvement in pain relief lasted 1 year^*,†,2

(SportVis® patients vs. placebo; p<0.05)

VAS: visual analogue scale; HA: hyaluronic acid/sodium hyaluronate.

*Patients rated pain on a 10 cm VAS (0 = no pain; 10 = maximal pain).

†A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 1% sodium hyaluronate in patients with chronic (> 3 months) lateral epicondylosis. Three hundred and thirty-one (331) patients were enrolled and randomized in a 1:1 ratio to either 1% sodium hyaluronate in 1.2 cc phosphate-buffered saline or 1.2 cc saline placebo. The average age was 49±15 years and 47±11 years for the HA and placebo groups, respectively. The primary outcome measures were an improvement on the VAS-pain at rest and following grip strength testing.

‡p<0.05 (within treatment groups).

¶p<0.05 (between treatment groups).

In acute ankle sprain

Significant improvement in pain relief began as soon as Day 4
and lasted up to 2 years^,†,3Significant improvement in pain relief began as soon as Day 4 and lasted up to 2 years^,†,3Significant improvement in pain relief began as soon as Day 4
and lasted up to 2 years^*,†,3

VAS: visual analogue scale; SC: standard of care; HA: hyaluronic acid; RICE: rest, ice, elevation, and compression; ITT: intent-to-treat

*Based on decrease from baseline of weight-bearing pain on a 10-point Likert scale (0–10 cm).

†A randomized, double-blind, placebo-controlled study to evaluate the long-term safety and efficacy of a peri-articular HA injection in acute lateral ankle sprain (Grade 1 or 2). One hundred and fifty-eight (158) patients were enrolled and randomized within 48 hours of injury in a 1:1 ratio to either HA + SC or placebo + SC. The usual standard of care consisted of RICE. The average age was 26±7 years and 24±8 years for the HA and placebo groups, respectively. The primary outcome was the decrease from baseline to Visit 2 (Day 8±1) in weight-bearing pain calculated in the ITT population.

‡p<0.05 (within treatment groups).

¶p<0.001 (between treatment groups).

Administration techniques

Make SportVis® part of your patients’ recovery.

SportVis® is administered via a peri-articular injection technique. This injection is delivered in an injury-specific fanning technique.

Watch the video for a demonstration
of a SportVis® injection under ultrasound guidance.Watch the video for a demonstration of a SportVis® injection under ultrasound guidance.Watch the video for a demonstration of a SportVis® injection under ultrasound guidance.

Lateral elbow tendinopathy administration

Dosage:

Two 1.2 mL SportVis® injections, 1 week apart.

A 27-gauge needle is recommended.

Two-plane fanning technique:

1Identify the tenderest point of the epicondyle by gentle palpation.Position the needle at 45° to the point of maximal pain of the lateral epicondyle.
2After puncture of the skin, angle the needle parallel to the skin and insert it toward the point of maximal pain on the lateral epicondyle. • Inject half of the contents as
the needle is withdrawn toward
the skin without exiting the skin.Inject half of the contents as the needle is withdrawn toward the skin without exiting the skin.Inject half of the contents as the needle is withdrawn toward the skin without exiting the skin.
3Rotate the needle 180° (opposite direction) and insert the needle parallel to the skin toward the point of maximal pain on the lateral epicondyle. • Inject the remaining contents as
the needle is withdrawn toward
the skin. Remove the needle from
the skin.Inject the remaining contents as the needle is withdrawn toward the skin. Remove the needle from the skin.Inject the remaining contents as the needle is withdrawn toward the skin. Remove the needle from the skin.
Flex and extend the elbow five times and then internally and externally rotate five times.

STABHA®: Soft Tissue Adapted Biocompatible Hyaluronic Acid

SportVis® is intended to relieve pain and restore function in:¹

Acute first- and second-degree ankle sprain;

Chronic (> 3 months) lateral epicondylalgia (tennis elbow).

Contraindication:

Patients with known sensitivity to sodium hyaluronate.

Relevant warnings and precautions:

SportVis® pre-filled syringes are single use only. The contents of the syringe should be used for one injection only. Any remaining sodium hyaluronate should be discarded. If a syringe is retained for a subsequent injection, there is a risk of contamination resulting in the possible infection of the patient, and/or foreign body reaction.
SportVis® should not be re-sterilized as the device performance may be compromised, which could cause serious harm to the patient’s health and safety.SportVis® should not be re-sterilized as the device performance may be compromised, which could cause serious harm to the patient’s health and safety.SportVis® should not be re-sterilized as the device performance may be compromised, which could cause serious harm to the patient’s
health and safety.
Sodium hyaluronate has the potential to occlude the vessels, which could result in embolism or infarction.
SportVis® should only be injected by a healthcare professional trained in peri-articular injection techniques.
SportVis® must not be injected into blood vessels or into a hematoma.
Direct injection into tendons should be avoided, as this can lead to rupture. Use of an ultrasound probe to guide the injection will minimize this risk.
Do not inject into the soft tissue of patients if the area of the injection site is infected or if there is evidence of acute or chronic skin disease in the area.Do not inject into the soft tissue of patients if the area of the injection site is infected or if there is evidence of acute or chronic skin disease in the area.Do not inject into the soft tissue of patients if the area of the injection site is infected or if there is evidence of acute or chronic skin disease
in the area.

For more information:

Please consult the SportVis® Package Insert for important information relating to adverse reactions and dosage and administration
that has not been discussed in this piece.Please consult the SportVis® Package Insert for important information relating to adverse reactions and dosage and administration that has not been discussed in this piece.Please consult the SportVis® Package Insert for important information relating to adverse reactions and dosage and administration
that has not been discussed in this piece.

The Package Insert is also available upon request by calling 1-888-550-6060 or by emailing [email protected].

References: 1. SportVis® Package Insert. PENDOPHARM. November 2020. 2. Petrella RJ et al. Management of tennis elbow with sodium hyaluronate periarticular injections. Sports Med Arthrosc Rehabil Ther Technol. 2010;2:4. 3. Petrella MJ et al. Original research: long-term efficacy and safety of periarticular hyaluronic acid in acute ankle sprain. Phys Sportsmed. 2009;37(1):64–70.

Relieve pain.Restore function.